Comparison of Lipid and Lipid-Associated Cardiovascular Risk Marker Changes After Treatment With Tocilizumab or Adalimumab in Patients With Rheumatoid Arthritis

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2015-207872
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Lipid Profile Changes in Patients With Rheumatoid Arthritis and Autoimmune Thyroiditis

Health of Society
2016English

Lipid Metabolism Disorders in Patients With Rheumatoid Arthritis

2019English

Economic Evaluation of Tocilizumab Monotherapy vs Adalimumab Monotherapy in Patients With Rheumatoid Arthritis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Rheumatoid Arthritis-Associated Uveitis Treated With Adalimumab

Klinika Oczna
MedicineOphthalmology
2019English

Adalimumab Discontinuation in Patients With Rheumatoid Arthritis After Achieving Sustained Remission

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2018English

Adalimumab With or Without Methotrexate in Juvenile Rheumatoid Arthritis

New England Journal of Medicine
Medicine
2008English

Long-Term Treatment of Rheumatoid Arthritis With Adalimumab

Open Access Rheumatology: Research and Reviews
Rheumatology
2013English

Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis

Arthritis Care and Research
Rheumatology
2017English

Laboratory and Febrile Features After Joint Surgery in Patients With Rheumatoid Arthritis Treated With Tocilizumab

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy